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Abstract: Resistance to apoptosis is one of the fundamental hallmarks of cancer. 
Recently, the selective induction of apoptosis in cancer cells has emerged as an 
exciting possibility for the development of future selective cancer therapy. This 
review will summarise the development of the major classes of small molecule “pro-
apoptotic” antitumour agents. 
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1. INTRODUCTION 
1.1 Apoptosis and Cancer Therapy 
Apoptosis (programmed cell death) is a well-ordered and tightly-regulated 
physiological process that plays a pivotal role in development, cancer, and normal 
ageing [1]. Defects in apoptotic pathways contribute fundamentally to a range of 
disease states, whether involving too much apoptosis (e.g. Alzheimer’s disease, 
multiple sclerosis) or too little (e.g. cancer, rheumatoid arthritis). Many reviews on the 
role and importance of apoptosis in cancer have been published and resistance to 
apoptosis is well known as one of the six hallmarks of cancer articulated by Hanahan 
and Weinberg [2].  
Apoptosis is induced via two main routes known as the intrinsic pathway 
(channelling through the mitochondria) and the extrinsic pathway (involving 
activation of death receptors) [3]. Mitochondria are well-established as central players 
in the cell death process, and mitochondrial membrane permeabilisation, leading to 
the subsequent release of apoptogenic factors (such as cytochrome c etc.) and caspase 
activation, usually has grave consequences for the cell [4]. 
The discovery of small molecule drugs capable of inducing apoptosis directly and 
selectively in cancer cells (pro-apoptotic cancer therapy) is a fundamental and highly 
attractive goal of cancer drug discovery. Pro-apoptotic agents would be expected to 
have the following beneficial effects compared to existing molecularly targeted and 
cytotoxic cancer therapeutics: 
• Tumour cells would be eliminated and would be unable to contribute to 
tumour relapse (as may the case for cytostatic agents), and drug resistance. 
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• Apoptosis is a particularly efficient mode of cell death (preferable to necrosis 
for example), and does not produce inflammation and damage to the 
surrounding tissue. 
• Agents that induce apoptosis directly would not be mutagenic, and would be 
less prone to development of drug resistance. Indeed the depolarisation of the 
mitochondrial membrane and release of pro-apoptotic factors such as 
cytochrome c most often represents the point-of-no-return for a cancer cell 
destined to die through apoptosis. 
• Severe toxicological side effects traditionally associated with cytotoxic 
(genotoxic) cancer chemotherapy should be avoided by selective pro-apoptotic 
activity on cancer cells lines at the expense of normal tissue. 
 
1.2 Scope of the Review 
Since most cancer chemotherapeutic agents (irrespective of their primary 
mechanism of action) ultimately lead to apoptotic cell death, the role of apoptosis in 
mediating the cell death process might be considered ubiquitous. It is not our intention 
to provide a global survey of antitumour agents that induce apoptosis. We will here 
focus on agents that are known to induce apoptosis directly, independent of p53 and 
other indirect factors such as cell cycle status. These direct pro-apoptotic effects are 
most often based on agents able to target mitochondria and their associated protein 
complexes. We will broadly focus on pro-apoptotic agents where there is reported 
selectivity between cancer and normal cells, i.e. supporting data regarding relative 
inactivity in normal cells.  
One related group of pro-apoptotic compounds that will not be described in 
detail here are the naturally occurring dietary agents that might best be described as 
 5 
cancer chemopreventative agents. Such agents in general have a complex 
pharmacology and pharmacokinetics, and rather weak pro-apoptotic activity, but are 
of interest here due to their minimal toxicity as dietary components. The green tea 
polyphenol epigallocatechin-3-gallate [5], the red grape/wine constituent resveratrol 
[6], and the chilli pepper constituent and vanilloid ligand capsaicin [7] provide 
examples of this class of agent. 
The review will concentrate exclusively on small molecules, and the 
development of “biological agents” such as agonistic antibodies targeting TRAIL 
death receptors (extrinsic apoptosis pathway) [8] will not be discussed here. 
 
2. PRO-APOPTOTIC ANTITUMOUR AGENTS IN DEVELOPMENT 
In a number of cases, the primary molecular target for selective pro-apoptotic 
molecules is unknown. We will classify recently reported selective pro-apoptotic 
agents in development for the treatment of cancer on the basis of molecular target, 
where this is known. This survey of pro-apoptotic agents provides a snapshot of what 
we consider to be the most important pro-apoptotic agents in development, and is by 
no means comprehensive. Our criteria for selection of compounds for inclusion here 
is based on: 
• Cellular potency of pro-apoptotic activity (in vitro / in vivo). 
• Lack of activity in cellular models of normal tissue and/or lack of in vivo 
toxicity. 
It is interesting to note that there are widely used anticancer agents in the clinic 
that have been studied with respect to their direct effects on isolated mitochondria and 
apoptosis induction. Since this review is limited to selective pro-apoptotic agents in 
development for cancer, studies in this area will not be considered in detail here (this 
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area has been reviewed, for example, by Debatin and co-workers [9]). For example, 
established cancer chemotherapeutic agents such as paclitaxel [10] (through 
interaction with the voltage-dependent anion channel) and etoposide [11] have 
previously been shown to induce mitochondrial membrane permeabilisation (MMP) 
and apoptosis in isolated mitochondria. 
 
2.1 Direct mitochondria-targeted agents 
The field of mitochondrial biochemistry has recently been undergoing 
something of a renaissance, in part due to the enticing possibility that mitochondria 
might represent a target for selective pro-apoptotic cancer therapy [12]. An early 
example of selective induction of apoptosis in vitro (albeit in a limited range of cancer 
cell lines) came from the synthesis and evaluation of a library (88 members) of 
amides based on a pro-apoptotic natural product from Isodon excisus [13]. The most 
potent compound of the series against the U-937 lymphoma cell line (IC50 44 µM) 
was found to be 1 (Figure 1), and cells treated with this agent showed several 
hallmarks of apoptotic cell death (e.g. caspase-3 induction and activity, and 
mitochondrial depolarization). Importantly compound 1 showed virtually no toxicity 
toward actively dividing mouse splenocytes (IC50 > 1000 µM), suggestive of selective 
cytotoxicity via apoptosis induction. 
 
Arsenic-based compounds 
Thiol-interactive arsenic-based compounds, such as phenylarsenoxide (PAO), 
have been found to induce MMP in isolated mitochondria [14] through a mechanism 
involving interaction with two unpaired cysteine residues in the adenine nucleotide 
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translocator (ANT), an important mitochondrial permeability transition pore protein 
that spans the inner mitochondrial membrane [15]. 
A tripeptide derivative of PAO, 4-(N-(S-glutathionylacetyl)amino)-
phenylarsenoxide (GSAO, 2, Figure 1) has been synthesised and also found to 
inactivate the ANT through cross-linking residues Cys160 and Cys257 in a stable ring 
structure [16]. GSAO caused a concentration-dependent increase in superoxide levels, 
ATP depletion, mitochondrial depolarization, and apoptosis selectively in 
proliferating, but not growth quiescent, endothelial cells. In addition, GSAO was 
selectively toxic towards endothelial cells, and inhibited angiogenesis in the chick 
chorioallantoic membrane and in solid tumours in mice, with no apparent toxicity at 
efficacious in vivo growth inhibitory doses. 
 
Jasmonates 
The jasmonates (3, Figure 1) are a group of plant stress hormones that have 
been found to inhibit proliferation and induce cell death in vitro in a range of human 
cancer cell lines (breast, prostate, melanoma, lymphoma, and leukemia) in a manner 
independent of cellular transcription, translation and p53 expression [17,18]. More 
recent studies on the mechanism of antitumour activity of jasmonates point decisively 
to the direct and selective action on human cancer cell mitochondria [19]. 
Jasmonates were found to induce membrane depolarization and cytochrome c 
release in intact Molt-4 cells. Importantly jasmonates induced swelling in 
mitochondria isolated from Hep3B hepatoma cells, but not in mitochondria isolated 
from 3T3 nontransformed (immortalised) cells or from normal lymphocytes, through 
interactions at the mitochondrial permeability transition pore complex (PTPC). In 
addition, jasmonates induce mitochondrial perturbation in chronic lymphocytic 
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leukaemia (CLL) cells taken from patients. Since proliferating normal cells were 
found to be insensitive to the effects of jasmonates, a mechanism exploiting 
mitochondrial characteristics that are differentially expressed in cancer cells is 
implied. 
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Fig. (1). Examples of mitochondria-targeted pro-apoptotic agents. 
 
2.2 Targeting tumour bioenergetic pathways 
Dichloroacetate (DCA) 
It is well established that cancer cells exhibit a unique metabolic profile 
whereby aerobic glycolysis is the main source of energy compared to oxidative 
phosphorylation in normal cells, a phenomenon known as the “Warburg effect” [20]. 
In a recent intriguing study, Bonnet et al. demonstrated that a simple commercially 
available chemical, the sodium salt of dichloroacetate (DCA) selectively induces 
apoptosis, reduces proliferation and inhibits growth of cancer cells by reversing this 
metabolic re-modelling process [21]. 
DCA-mediated antitumour effects were found to mainly involve the inhibition 
of mitochondrial pyruvate dehydrogenase kinase (PDK2), causing depolarisation of 
 9 
the mitochondrial membrane and allowing efflux of pro-apoptotic factors and 
apoptosis induction [21]. In addition, it was also demonstrated that DCA causes the 
up-regulation and activation of Kv1.5 potassium channels through the inhibition of 
NFAT1 (nuclear factor of activated T lymphocytes) leading to a decreased cellular 
[K+]I and hence activating caspases. In vivo studies have shown that using clinically 
relevant DCA doses in the drinking water of rat models effectively led to the 
inhibition and prevention of tumour growth with no observed toxicity [21]. Indeed, 
these findings raise hopes of having an orally potent and cost-effective antitumour 
agent. However, growing evidence suggests that the plasticity of tumour cells enables 
them to activate other non-glycolytic pathways to secure their energy, posing issues of 
drug resistance [22]. 
 
2.2   XIAP Targeted agents: 
Inhibitors of apoptosis proteins (IAPs) are endogenous caspase inhibitors that 
bind and inhibit caspases -3, -7 and -9. Eight members of the IAP family are known 
so far [23], of which X-linked inhibitor of apoptosis protein (XIAP) is the best 
characterized in term of its inhibitory mechanism. XIAP has three BIR domains (BIR 
1-3) and a RING finger that binds and inhibits caspases [24]. The BIR-3 domain of 
XIAP inhibits caspase-9, while BIR-1 and -2 are more specific for caspases -3 and -7 
[25-27]. 
Smac-DIABLO is a protein released from the mitochondria in response to 
apoptotic stimuli and directly interacts with XIAP, functioning as an endogenous 
inhibitor of the IAP family [26,27]. Targeting the IAP family came from the finding 
that the levels of different IAP family members were elevated in several tumours, thus 
providing a possible mechanism for inducing apoptosis directly and specifically to 
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treat cancer [28-30]. Since small molecule inhibitors of XIAP have been recently 
reviewed [31-33], we will focus here on two examples of XIAP inhibitors selected 
from the literature on the basis of their pro-apoptotic properties. 
 
Embelin 
Embelin (4) was discovered through computational structure-based screening 
of an in-house traditional herbal medicine three-dimensional structure database of 
8221 individual natural products [34]. Embelin, extracted from the Japanese Ardisia 
herb, was found to bind to the XIAP BIR-3 domain. It selectively inhibited cell 
growth and induced apoptosis in prostate cancers known to over-express XIAP with 
minimal effect on normal cells. Embelin inhibited cell growth of both PC-3 and 
LNCap cells with an IC50 of 3.7 µM and 5.7 µM respectively, whilst in a caspase 
activation assay, embelin was found to effectively activate caspase-9 and to induce 
early apoptosis. More recent studies on embelin derivatives have identified new and 
potent XIAP BIR3 inhibitors with pro-apoptotic properties in human cancer cells [35]. 
 
Smac mimetics 
Most of the designed Smac mimetics depend on replacing the valine in the 
Smac based AVPI peptide with an unnatural amino acid. These Smac mimetic XIAP 
inhibitors act by binding more strongly to BIR-3, inhibiting the binding of caspase-9 
to XIAP at this site thus antagonizing its inhibitory effect and inducing apoptosis. 
A series of tripeptides was described by Oost et al. [36] that bind to XIAP 
BIR-3 domain with nanomolar affinities. The most active compound of the series (5) 
showed a wide range of potencies against a diverse panel of human cancer cell lines 
ranging from a single-digit nanomolar activity in certain types to no activity at up to 
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50 µM concentration in other cell types. The most potent in vitro activity was 
observed against the human breast cancer cell lines BT-549 and MDA-MB-231, the 
melanoma cell line SK-MEL-5, and the acute promyelocytic leukaemia HL-60. 
Interestingly, there was no correlation between the potency of (5) and the expression 
of XIAP. Measuring caspase-3 activation in MDA-MB-231 cells treated with (5) 
showed an up to 8-fold increase in caspase-3 activity in a dose-dependent manner. 
Apoptosis was induced by (5) in absence of an identified apoptotic stimuli. In in vivo 
testing (MDA-MB-231 flank breast cancer xenograft model), a 20 mg/kg/day dose of 
(5) inhibited tumour growth rates by 50-60%. 
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Fig. (2). Examples of XIAP-targeted pro-apoptotic agents. 
 
2.3   Bcl-2 targeted agents 
The B-cell lymphoma 2 (Bcl-2) family of proteins is composed of more than 
20 members [37-39]. Some members such as Bcl-2, BclXL, Bcl-w and Mcl-1 are anti-
apoptotic, whilst others are pro-apoptotic such as Bax, Bak, Bid and Bim. Both family 
members cooperate through protein-protein interactions to mediate the intrinsic 
apoptotic pathway [40,41]. 
Anti-apoptotic Bcl-2 family members protect cells from apoptosis by 
inhibiting the action of pro-apoptotic members [42,43]. Three-dimensional studies of 
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anti-apoptotic Bcl-2 proteins revealed the presence of a hydrophobic groove that acts 
as a binding site for the BH3 peptide domain of pro-apoptotic Bcl-2 members [44]. 
Agents that are designed to target these binding grooves are predicted to induce 
apoptosis in cancer cells (which over-express these anti-apoptotic proteins) by 
antagonizing their protective effect. 
Over the past 10 years, several non-peptidic small molecule inhibitors to anti-
apoptotic Bcl-2 proteins have been introduced and some of them are already in 
clinical trials as single-agent chemotherapy, such as the Phase 1 orally bioavailable 
pan-Bcl-2 inhibitor AT-101 from Ascenta Therapeutics [45]. Since the development 
of Bcl-2 modulatory small molecules as potential anticancer therapeutics has been 
reviewed in recent years (for examples, see [8,46]), discussion here will be limited to 
the most relevant potent and selective pro-apoptotic agents only. 
 
HA 14-1 
Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-
carboxylate (HA 14-1, 6a) was one of the first identified small molecule inhibitors of 
anti-apoptotic Bcl-2 proteins [47]. HA 14-1 competes with the Bak BH3 domain for 
binding to the Bcl-2 hydrophobic groove with a Ki value of 9 µM. It was found to 
induce apoptosis in human acute myeloid leukaemia (HL-60) cells and H1299 cells at 
a concentration of 20-50 µM [47] and was found to induce apoptosis selectively in 
cell lines that over-express anti-apoptotic Bcl-2 proteins [48-49]. 
Studies made to ascertain the mechanism of apoptotic action revealed that HA 
14-1 causes a release of Ca2+ from the endoplasmic reticulum and decreases the 
mitochondrial membrane potential resulting in a release of cytochrome c into the 
cytosol [47], which in turn forms a complex with Apaf-1 causing activation of 
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caspase-9 [50]. Several studies have shown that HA 14-1 potentiates the action of 
many anti-cancer agents by antagonizing the Bcl-2 which protect cells from apoptosis 
[51-52] suggesting its use in combined therapy. Modification of the structure of HA 
14-1 led to compound (6b) with a GI50 of 0.99 µM for Jurkat cells (compared to a 
GI50 of 20 µM for HA 14-1) [53]. 
 
Gossypol 
(-)- Gossypol (7), a natural polyphenolic compound isolated from cotton seed, 
was identified as a small molecule inhibitor of Bcl-2 and BclXL proteins [54]. (-)-
Gossypol binds to the BH3 binding groove of Bcl-2, BclXL and Mcl-1 with Ki values 
of 320, 480 and 180 nM respectively, and induces apoptosis in Jurkat cells over-
expressing Bcl-2 and BclXL with IC50 values of 18.1 and 22.9 µM respectively [54]. 
Induction of apoptosis with (-)-gossypol is associated with cytochrome c release and 
caspase-3 activation [54]. Gossypol has shown to possess antitumour activity against 
several tumor types [55-59] and it is now in clinical trials as a novel orally 
bioavailable anticancer agent. 
 
TW-37 
TW-37 (8) is another polyphenolic compound discovered through structure-
based design that binds to the BH3 binding groove of Bcl-2 [60]. TW-37 was found to 
bind to Bcl-2, BclXL and Mcl-1 with Ki values of 290, 1100 and 260 nM respectively, 
while ELISA assay showed TW-37 to bind to Bcl-2 with an IC50 value of 0.7 µM. In 
vitro growth inhibition assay showed that TW-37 inhibits cell growth of PC-3 cancer 
cells with an IC50 of 200 nM. The TUNEL assay, on the other hand, showed that TW-
37 can potently induce apoptosis, where 90% of PC-3 cancer cells treated with TW-37 
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(5 µM) underwent apoptosis [60]. In vitro, TW-37 showed significant 
antiproliferative effects in a chemoresistant WSU-DLCL2 lymphoma cell line and in 
primary cells obtained from a lymphoma patient with no effect on normal peripheral 
blood lymphocytes. Co-immunoprecipitation experiments showed that TW-37 
disrupted heterodimer formation between Bax or truncated-Bid and antiapoptotic Bcl-
2 and caused apoptotic cell death [61]. Additional anti-angiogenic properties 
associated with TW-37 have also been reported (outside the scope of this review) 
[62]. 
 
ABT 737 
ABT 737 (9) was discovered through high-throughput NMR-based screening 
of a chemical library to identify small molecules that bind to the BH3 binding groove 
of BclXL [64]. ABT-737 was found to bind to Bcl-2, BclXL and Bcl-w with high 
affinity (Ki ≤ 1 nM). ABT-737 did not itself induce release of cytochrome c, but 
inhibited Bcl-2 protection at concentrations ≤ 10 nM by blocking the inhibition of 
Bid-mediated cytochrome c release through binding to the BH3 binding groove of 
Bcl-2. This binding disrupted the protein-protein interaction between BclXL and pro-
apoptotic Bcl-2 proteins. 
ABT-737 was found to be active both as a single agent or when used in 
combination with other chemotherapies or radiation, where it reduced the EC50 of 
several antitumour agents by 2-4 fold. As a single agent, it displayed potent 
cytotoxicity in several lymphomas and SCLC, where it had an EC50 of 0.13-0.85 µM 
when used in t(14:18) chromosomal translocation-containing lymphoma cell lines. As 
an inhibitor of anti-apoptotic Bcl-2 ABT-737 exhibited pro-apoptotic activity and 
induced apoptosis in a concentration-dependent matter in patient-derived chronic 
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lymphocytic B-cell leukaemia (CLC). In vivo, ABT-737 caused complete regression 
of established SCLC tumour xenografts as a result of apoptotic cell death. ABT-737 
induced apoptosis selectively in cancer cells without affecting normal cells, where a 
significant increase in caspase-3 was noticed in tumour cells but not in liver, heart or 
intestinal normal cell lines [63]. 
 
YC 137 
YC 137 (10) was discovered through structure-based design of small molecule 
inhibitors of anti-apoptotic Bcl-2. YC 137 was found to inhibit the binding of Bid-
BH3 peptide to the Bcl-2 hydrophobic groove [64]. Hematopoeitic progenitors and 
cancer cells over-expressing Bcl-2 were found to be more sensitive to YC 137, and 
induction of apoptosis by this compound was selective to cancer cells expressing high 
levels of Bcl-2 such as CD34+ progenitors, myoblasts and peripheral blood 
mononuclear cells, without affecting normal cells. In vitro selection of breast cancer 
cell lines resistant to YC 137 showed a reduced expression of Bcl-2 correlating with 
low activation of signal transducer and activator of transcription 3 (Stat3) in addition 
to reduced expression of the human growth factor receptor-2 (HGR2), and such cells 
were found to be more sensitive to apoptosis induced by chemotherapy [64]. 
 
Flexible heteroarotinoids (Flex-Hets) 
 Flexible heteroarotinoids, more commonly shortened to Flex-Hets, represent a 
novel class of potent antitumour compounds which selectively induce apoptosis in a 
wide range of cancer cell lines [65]. The lead compound in this class SHetA2 (11) 
induces high levels of apoptosis at low micromolar concentrations, with a broad 
spectrum of activity in the NCI human cancer cell line panel [66] as well as cervical 
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and head & neck cancer cell lines [67].  
Flex-Hets were developed from the antitumour heteroarotinoids by 
introducing urea or thiourea linkers to confer more flexibility to their structures [65]. 
Whilst nuclear retinoic acid receptor activation accounts for most of the antitumour 
properties of heteroarotinoids, Flex-Hets were found to have a distinct mechanism of 
action which entails the activation of the intrinsic mitochondrial pathway as well as 
the generation of reactive oxygen species (ROS) [66], as a consequence of 
mitochondrial swelling [68].  In addition, it was also demonstrated that the observed 
differential effects of Flex-Hets on cancer cells versus normal cells are likely 
attributed to their targeting of Bcl-2 family proteins. Flex-Hets reduce the levels of 
anti-apoptotic BclXL and Bcl-2 proteins in cancer cell lines in contrast to normal cell 
lines where the expression of these proteins increases; pro-apoptotic Bax proteins 
levels remained unaltered in both cell types [68]. SHetA2 exhibited potent and 
selective antitumour properties in preclinical in vivo studies [69], suggesting 
translation of this work into the clinical setting in the near future. 
 
Stapled peptides 
A highly promising approach towards targeting α-helical protein-protein interactions, 
using peptides stabilised using a chemical strategy termed “hydrocarbon stapling”, 
has been applied to generate helical, protease-resistant, and cell-permeable BH3 
peptide derivatives that bind with high affinity to multidomain Bcl-2 family members. 
One of these “stabilized alpha-helix of Bcl-2 domain” (SAHB) peptides was found to 
effectively inhibit the growth of human leukaemia xenografts in vivo [70], and to 
trigger the functional activation of pro-apoptotic Bax at nanomolar doses in vitro [71]. 
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Further development of these stable and specific stapled peptides is eagerly 
anticipated. 
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Fig. (3). Examples of Bcl-2 family-targeted pro-apoptotic agents. 
 
2.4   Pro-apoptotic agents with miscellaneous (defined) molecular targets 
3-Aryl-5-aryl-1,2,4-oxadiazoles 
5-(3-Chlorothiophen-2-yl)-3-(4-trifluoromethylphenyl)-1,2,4-oxadiazole (12) 
was identified as a novel apoptosis inducer through a high-throughput caspase- and 
cell-based screening assay [72]. The apoptosis inducing activity of this compound was 
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further characterized by a caspase-activation assay in SKBr3 cells, where a reduction 
of pro-caspases and appearance of active caspase-3 and -7 was identified. Compound 
12 induced apoptosis selectively in certain cancer cell lines including the breast 
cancer cell lines T47D and ZR75-1 and colorectal cancer cell lines DLD-1 and HT29, 
with EC50’s in the range 0.44 to 3.34 µM [72]. 
A chemical genetics approach was applied to identify the molecular target of 
this compound, where several key genes including cyclin D1, transforming growth 
factor-beta1, p21, and insulin-like growth factor-BP3 (IGFBP-3) were found to be 
altered in cells that are sensitive to this compound. Applying a photoaffinity-labelling 
methodology, tail interacting protein 47 (TIP47), an insulin-like growth factor II (IGF 
II) receptor binding protein, was identified as the molecular target [73], where it was 
down-regulated in cells treated with this compound. TIP47 is known to bind to 
mannose-6-phosphate receptor (MPR) and it plays a role in the transport of this 
receptor from endosomes to the golgi network [74]. The over-expression of TIP47 in 
several tumour types has also been reported [75], suggesting that it may be a 
potentially useful anticancer target. 
 
Gambogic acid derivatives 
Gambogic acid (13), a natural product isolated from the resin of the Garcinia 
Hurburys tree, was first identified as a potent apoptosis inducer through a high-
throughput screening assay [76]. The apoptosis inducing activity of this compound 
was characterized by a caspase activation assay in T47D cancer cells, where (13) had 
an EC50 of 0.78 µM [76]. Further indication of the apoptosis inducing activity came 
from the observed nuclear fragmentation when cells were treated with (13) which 
could be protected by a pan-caspase inhibitor (EP1013) [77]. In flow cytometry 
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assays in T47D cells, (13) was observed to induce apoptosis independent of cell cycle 
status [74]. Activation of caspase-8, cleavage of Bid and release of cytochrome c from 
the mitochondria were all observed after treating Jurkat cells with (13) [78]. 
The molecular target of gambogic acid derivatives was reported to be the 
transferrin receptor I (TfR) [78], a trans-membrane protein that plays a role in the 
transport of iron into cells through its interaction with transferrin. Binding assays 
showed that there is a good correlation between the affinity of gambogic acid 
derivatives to TfR and their ability to induce apoptosis. The binding site for (13) was 
found to be different from that of transferrin, suggesting a unique binding site and 
mechanism of action of these compounds [79]. Moreover, TfR was reported to be 
over-expressed in certain tumour types [79], suggestive that inhibitors of TfR could 
have useful anti-cancer activity. 
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Fig. (4). Examples of pro-apoptotic agents with miscellaneous (defined) targets. 
 
3. FUTURE PERSPECTIVES 
 The direct and selective induction of apoptosis in human cancer cells through 
targeting components of the mitochondrial membrane (e.g. the Bcl-2 family) has been 
illustrated. Future challenges remain in translating promising pro-apoptotic molecules 
into the clinic, and further delineation of their pharmacological basis for antitumour 
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activity. The prospect of mitochondrially-targeted agents exhibiting potent but 
selective activity against human cancer cells with a wide therapeutic window, remains 
an enticing prospect. 
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